A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Inclusion Criteria * Previously untreated, apparently resectable, adenocarcinoma of the pancreas at registration. * Age greater than or equal to 18 years * Eastern Cooperative Oncology Group performance status of 0-2. * Standard laboratory criteria for hematologic, biochemical, and urinary indices within a range that, in the opinion of the physician, clinically supports enrollment of the patient on the trial. Note: subjects must have: Creatinine \< 2x Upper Normal Limit , Transaminases \< 3x Upper Normal Limit, Neutrophils \>1.5x109/L, and Platelets \>100,000/mm3 * Ability to provide written informed consent Exclusion Criteria * Patients with hypercalcemia (blood levels greater than 11.5 mg/dL; in patients with kidney disease, blood calcium levels must be 9.5 mg/dL or lower before starting paricalcitol). * Patients who are currently pregnant, planning to become pregnant, or breast-feeding. * Patients who, in the opinion of the physician, would not be clinically appropriate for receipt of the therapy regimen associated with participation